Adcomm backs use of minimal residual disease in multiple myeloma accelerated approvals
A new oncology drug endpoint, based on what’s known as minimal residual disease, gained the backing of FDA advisors, potentially opening the door to new …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
